<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014206</url>
  </required_header>
  <id_info>
    <org_study_id>B1851121</org_study_id>
    <nct_id>NCT03014206</nct_id>
  </id_info>
  <brief_title>Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-</brief_title>
  <official_title>Prevenar (13v) Adult Special Investigation (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to understand the following items in post-marketing actual clinical settings
      to evaluate the safety of 13vPnC administered as a single dose in the elderly (adults aged
      65 years or older).

        1. To confirm the use in actual clinical settings

        2. To confirm the occurrence of adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter open-label cohort conducted in patients vaccinated with the
      Product; for which, case report forms will be recorded based on data presented in medical
      records obtained from day-to-day clinical treatment and diagnosis. &quot;Pneumococcal vaccine
      health study diary&quot; will be implemented to collect accurate safety data; to which, vaccine
      recipients will be asked directly to cooperate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>Number of Subjects reporting Adverse Events</measure>
    <time_frame>28Days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">696</enrollment>
  <condition>Adult Not Younger Than 65 Years</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Geriatric patients vaccinated with this product (adult not younger than 65 years)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Geriatric patients vaccinated with this product (adult not younger than 65 years)

          2. Consent of vaccine recipients [Vaccine recipient (or his/her legally acceptable
             representative) must sign and date the consent form warranting that the relevant
             information concerning this Study was appropriately communicated to the recipient].

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851121&amp;StudyName=Prevenar%20%2813v%29%20Adult%20Special%20Investigation%20%28regulatory%20Post%20Marketing%20Commitment%20Plan%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>July 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
